Login / Signup

An overview of the currently available and emerging long-acting formulations of risperidone for schizophrenia and bipolar disorder.

Justin FadenCamila RamirezVanessa MartinezLeslie Citrome
Published in: Expert review of neurotherapeutics (2024)
There is an expanding number of currently available LAI antipsychotic medications giving patients and providers an opportunity to personalize and individualize care. Rates of adherence to treatment in patients with schizophrenia and bipolar disorder are low, and individualizing care can help improve this. The risperidone LAI treatment landscape includes five options approved by the U.S. Food and Drug Administration, with others under clinical development. These options differ in regard to mode of administration, approved indications, available dose strengths, injection intervals, needle size, injection volume, storage, and other variables. Prescribers should be familiar with these differing options to help patients find the best fit for their individual needs.
Keyphrases